Molecular structure of Regorafenib, CAS Number: 755037-03-7
Regorafenib (CAS 755037-03-7)
See product citations (3)
Alternate Names:
Regorafenib is also known as BAY 73-4506.
Application:
Regorafenib is a multi-kinase inhibitor that is orally bioavailable and displays anticancer properties.
CAS Number:
755037-03-7
Molecular Weight:
482.82
Molecular Formula:
C21H15ClF4N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Regorafenib is widely utilized in research focused on kinase activity and signal transduction pathways. This compound is specifically employed to study its inhibitory effects on multiple tyrosine kinases, which are key regulators of cellular processes such as growth, migration, and survival. Researchers use Regorafenib to investigate the molecular mechanisms by which kinases influence tumor growth and metastasis in various cancer models. Additionally, Regorafenib is used to explore the effects of kinase inhibition on angiogenesis, the process of new blood vessel formation, which is for tumor development and progression. The insights gained from studies using Regorafenib contribute significantly to the understanding of cellular signaling networks and their impact on disease pathology.
Regorafenib (CAS 755037-03-7) References
- Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib. | Lyseng-Williamson, KA. 2013. BioDrugs. 27: 525-31. PMID: 23975637
- Prevention and management of adverse events related to regorafenib. | De Wit, M., et al. 2014. Support Care Cancer. 22: 837-46. PMID: 24337717
- Regorafenib-induced hyperammonemic encephalopathy. | Kuo, JC., et al. 2014. J Clin Pharm Ther. 39: 446-8. PMID: 24707992
- Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. | McLellan, B., et al. 2015. Ann Oncol. 26: 2017-26. PMID: 26034039
- Regorafenib: a promising treatment for hepatocellular carcinoma. | Cerrito, L., et al. 2018. Expert Opin Pharmacother. 19: 1941-1948. PMID: 30345837
- Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. | Shigeta, K., et al. 2020. J Immunother Cancer. 8: PMID: 33234602
- Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. | Ou, DL., et al. 2021. J Immunother Cancer. 9: PMID: 33753566
- Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer. | Liu, J., et al. 2022. J Colloid Interface Sci. 607: 229-241. PMID: 34500422
- Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. | Dai, Z., et al. 2022. Cancer Lett. 524: 161-171. PMID: 34687791
- Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. | Chiang, IT., et al. 2022. Neurotherapeutics. 19: 616-634. PMID: 35267171
- Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. | Chang, YC., et al. 2022. Cell Death Dis. 13: 391. PMID: 35449153
- A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. | Kim, RD., et al. 2022. Eur J Cancer. 169: 93-102. PMID: 35526308
- Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. | Akin Telli, T., et al. 2022. Cancer Treat Rev. 110: 102460. PMID: 36058142
- Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. | Liu, J., et al. 2022. Front Immunol. 13: 992611. PMID: 36119072
Inhibitor of:
2900053A13Rik, 7420461P10Rik, AKIP, ALG11, Angptl1, ASPH, BAALC, BBS8, BSPH1, c-Kit, CA19-9, CD45, CYBASC3, CYHR1, DNAJC25-GNG10, EG-VEGF, EGFL6, EGFL7, ETL, EVI2B, EYA1, FAM75C2, FHL-5, Fis1, Flk-1, FLTR1, Gm3336, Gm960, H2-Kk, HBV xAg, Hepatocellular Carcinoma Marker, HHCM, KHS, Lefty, MAGE-D4B, MMD, MSLNL, neuropilin, NUCKS, Olr1029, Olr1052, Olr1060, Olr1061, Olr1126, Olr1234, Olr1259, Olr129, Olr1334, Olr1350, Olr1384, Olr1398, Olr1528, Olr1558, Olr1642, Olr165, Olr170, Olr175, Olr322, Olr348, Olr354, Olr363, Olr37, Olr375, Olr496, Olr541, Olr653, Olr696, Olr714, Olr72, Olr736, Olr750, Olr836, Olr838, Olr964, Olr982, PATE-N, PDGF-B, PDGFR-beta, PIG-F, Protein tyrosine phosphatase receptor (PTPR), PTPκ, PTPRQ, RASGEF1A, Renal Cell Carcinoma, Ret, RETL2, RGL1, RNF213, robo4, RUSC2, SBK1, SCF, Sm D1, SMPD5, Srb4, ST, TEM7, TRBV3, UGT1A1, Vasohibin-2, VEGF-D, VG5Q, VHR, Vmn2r5, VSIG10, and Zfp804b.Activator of:
CCDC110, CRP2, CTU2, EGFL3, Endoglin, MFAP3L, PlGF, SK2, Tie-1, and Vasohibin-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Regorafenib, 25 mg | sc-477163 | 25 mg | $320.00 | |||
Regorafenib, 50 mg | sc-477163A | 50 mg | $430.00 |